Fig. 6

C-Kit⁺-LSECs were lack in NASH and BMT of C-Kit⁺-BMCs could protect against NASH in vivo. A, B Representative images and calculation of IF staining for C-KIT (green IF) and CD31 (red IF) in liver tissues of control and MCD mice (× 200). DAPI (blue) was used for nuclear staining. Arrows (yellow) indicated C-Kit⁺CD31⁺-LSECs. C, D Representative images and calculation of IF staining for C-KIT (green IF) and CD31 (red IF) in liver tissues of NASH and AIH patients (× 400). DAPI (blue) was used for nuclear staining. C–K We transplanted C-Kit⁺- or C-Kit⁻-BMCs into MCD mice. Images and calculation of ORO (E/F), H&E (E/G) and Masson (E/H) staining of liver tissues in 2 groups. I Hepatic C-Kit mRNA was examined by qPCR in 2 groups. J, K Hepatic protein levels of C-KIT were examined by western blot in 2 groups. The p-value indicated statistical significance compared to control mice, AIH patients or MCD_C-Kit⁻-BMC mice